Pharmacogenomic tests used to guide the clinical treatment of major depressive disorder (MDD) must be carefully validated. An important assessment of validity is the ability to predict blood levels of drugs, which reflect impaired metabolism. Historically, the metabolic impact of individual genes has been assessed; however, we now know that several genes are often involved in drug metabolism. Here, we assessed the ability of individual pharmacokinetic genes (CYP2C19, CYP2D6, CYP3A4) and a combinatorial pharmacogenomic test (GeneSight Psychotropic®; weighted evaluation of the three genes) to predict blood levels of citalopram / escitalopram in patients with MDD. Patients from the genomic trial to improve depression decisions (GUIDED) who were taking citalopram / escitalopram during screening and who had data on blood levels were included (N = 191). In the multivariate analysis of the individual genes and of the combinatorial pharmacogenomic test separately (adjusted for age, smoking status), the F statistic for the combinatorial pharmacogenomic test was 1.7 to 2.9 times higher than the individual genes, showing that it explained a greater variance in citalopram / escitalopram blood levels. In the multivariate analysis of individual genes and the combinatorial pharmacogenomics test together, only the combinatorial pharmacogenomics test remained significant. Overall, this demonstrates that the combinatorial pharmacogenomic test was a better predictor of citalopram / escitalopram blood levels compared to individual genes.
Research Article: Neurological Disorders
Research Article: Neurological Disorders
Research Article: Neurological Disorders
Research Article: Neurological Disorders
Research Article: Neurological Disorders
Research Article: Neurological Disorders
Image: Neurological Disorders
Image: Neurological Disorders
Research Article: Neurological Disorders
Research Article: Neurological Disorders
Scientific Tracks Abstracts: Neurological Disorders
Scientific Tracks Abstracts: Neurological Disorders
Posters & Accepted Abstracts: Neurological Disorders
Posters & Accepted Abstracts: Neurological Disorders
Scientific Tracks Abstracts: Neurological Disorders
Scientific Tracks Abstracts: Neurological Disorders
Posters-Accepted Abstracts: Neurological Disorders
Posters-Accepted Abstracts: Neurological Disorders
Scientific Tracks Abstracts: Neurological Disorders
Scientific Tracks Abstracts: Neurological Disorders
Neurological Disorders received 1343 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 